Tennessee Retina
- Type
- Non-covered entity
- Where
- Nashville, TN
- Received
- $3,053,061 in 252 records, 2019 to 2024 ($0 general, $3,053,061 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | Research payment | 4 | $80,313 |
| 2023 | Research payment | 2 | $93,472 |
| 2021 | Research payment | 87 | $1,181,490 |
| 2020 | Research payment | 64 | $1,074,699 |
| 2019 | Research payment | 95 | $623,085 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genentech, Inc. | 196 | $2,874,999 | 2019–2021 |
| EyePoint Pharmaceuticals US, Inc. | 1 | $92,822 | 2023 |
| Alimera Sciences, Inc. | 5 | $80,963 | 2023–2024 |
| Mylan Technologies Inc. | 50 | $4,276 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 252 | $3,053,061 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-11 | Alimera Sciences, Inc. | $8,225 | Research payment | Cash or cash equivalent | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | The SYNCHRONICITY Study | 2024 |
| 2024-12-11 | Alimera Sciences, Inc. | $1,028 | Research payment | Cash or cash equivalent | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | The SYNCHRONICITY Study | 2024 |
| 2024-08-08 | Alimera Sciences, Inc. | $11,310 | Research payment | Cash or cash equivalent | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | The SYNCHRONICITY Study | 2024 |
| 2024-05-17 | Alimera Sciences, Inc. | $59,750 | Research payment | Cash or cash equivalent | YUTIQ Drug, Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | The SYNCHRONICITY Study | 2024 |
| 2023-12-20 | Alimera Sciences, Inc. | $650 | Research payment | Cash or cash equivalent | SYNCHRONICITY | 2023 | |
| 2023-09-21 | EyePoint Pharmaceuticals US, Inc. | $92,822 | Research payment | Cash or cash equivalent | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis | 2023 |
| 2021-12-22 | Genentech, Inc. | $137,721 | Research payment | Cash or cash equivalent | Drug | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2021 |
| 2021-12-22 | Genentech, Inc. | $35,289 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-12-15 | Genentech, Inc. | $46,541 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY | 2021 |
| 2021-12-15 | Genentech, Inc. | $25,917 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2021 |
| 2021-12-03 | Genentech, Inc. | $12,736 | Research payment | Cash or cash equivalent | Drug | FARICIMAB DME LONG TERM EXTENSION RHONE X | 2021 |
| 2021-11-11 | Genentech, Inc. | $16,388 | Research payment | Cash or cash equivalent | Drug | PH1 SAD OF IL33 IN GEOGRAPHIC ATROPHY | 2021 |
| 2021-10-27 | Genentech, Inc. | $28,041 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII | 2021 |
| 2021-10-27 | Genentech, Inc. | $8,639 | Research payment | Cash or cash equivalent | SUSVIMO Drug, Immunology and Ophthalmology | MAD TO ASSESS THE SAFETY TOLERABILITY AND PK PD IN NAMD PATIENTS | 2021 |
| 2021-10-22 | Genentech, Inc. | $1,721 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII RHINE | 2021 |
| 2021-10-06 | Genentech, Inc. | $6,362 | Research payment | Cash or cash equivalent | Drug | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION | 2021 |
| 2021-10-04 | Genentech, Inc. | $56,411 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY | 2021 |
| 2021-10-01 | Mylan Technologies Inc. | $178 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-10-01 | Mylan Technologies Inc. | $56 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-10-01 | Mylan Technologies Inc. | $14 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-10-01 | Mylan Technologies Inc. | $13 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-10-01 | Mylan Technologies Inc. | $5 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-09-27 | Genentech, Inc. | $108,927 | Research payment | Cash or cash equivalent | Drug | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2021 |
| 2021-09-27 | Genentech, Inc. | $14,773 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-09-27 | Genentech, Inc. | $2,995 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-09-01 | Mylan Technologies Inc. | $288 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-09-01 | Mylan Technologies Inc. | $91 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-09-01 | Mylan Technologies Inc. | $22 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-09-01 | Mylan Technologies Inc. | $20 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-09-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-08-25 | Genentech, Inc. | $13,062 | Research payment | Cash or cash equivalent | Drug | FARICIMAB DME LONG TERM EXTENSION RHONE X | 2021 |
| 2021-08-09 | Genentech, Inc. | $1,215 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII RHINE | 2021 |
| 2021-08-01 | Mylan Technologies Inc. | $292 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-08-01 | Mylan Technologies Inc. | $92 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-08-01 | Mylan Technologies Inc. | $22 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-08-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-08-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-07-26 | Genentech, Inc. | $19,920 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII | 2021 |
| 2021-07-21 | Genentech, Inc. | $8,400 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII RHINE | 2021 |
| 2021-07-01 | Mylan Technologies Inc. | $295 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-07-01 | Mylan Technologies Inc. | $93 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-07-01 | Mylan Technologies Inc. | $23 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-07-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-07-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-06-27 | Genentech, Inc. | $133,645 | Research payment | Cash or cash equivalent | Drug | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2021 |
| 2021-06-27 | Genentech, Inc. | $10,193 | Research payment | Cash or cash equivalent | Drug | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2021 |
| 2021-06-27 | Genentech, Inc. | $8,085 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-06-27 | Genentech, Inc. | $2,995 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-06-21 | Genentech, Inc. | $71,878 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM OF RANIBIZUMAB EXTENSION STUDY | 2021 |
| 2021-06-15 | Genentech, Inc. | $70,930 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2021 |
| 2021-06-01 | Mylan Technologies Inc. | $297 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-06-01 | Mylan Technologies Inc. | $94 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-06-01 | Mylan Technologies Inc. | $23 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-06-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-06-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-05-21 | Genentech, Inc. | $10,144 | Research payment | Cash or cash equivalent | Drug | FARICIMAB DME LONG TERM EXTENSION RHONE X | 2021 |
| 2021-05-01 | Mylan Technologies Inc. | $303 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-05-01 | Mylan Technologies Inc. | $96 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-05-01 | Mylan Technologies Inc. | $23 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-05-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-05-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-04-22 | Genentech, Inc. | $42 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2021 |
| 2021-04-20 | Genentech, Inc. | $801 | Research payment | Cash or cash equivalent | Drug | PHASE 2 OF RO7171009 IN GA | 2021 |
| 2021-04-14 | Genentech, Inc. | $30,426 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII | 2021 |
| 2021-04-14 | Genentech, Inc. | $16,565 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII RHINE | 2021 |
| 2021-04-01 | Mylan Technologies Inc. | $301 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-04-01 | Mylan Technologies Inc. | $95 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-04-01 | Mylan Technologies Inc. | $23 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-04-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-04-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-03-18 | Genentech, Inc. | $84,395 | Research payment | Cash or cash equivalent | Drug | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2021 |
| 2021-03-18 | Genentech, Inc. | $25,209 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2021 |
| 2021-03-18 | Genentech, Inc. | $11,567 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-03-18 | Genentech, Inc. | $2,995 | Research payment | Cash or cash equivalent | Drug | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2021 |
| 2021-03-15 | Genentech, Inc. | $106,766 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2021 |
| 2021-03-15 | Genentech, Inc. | $3,398 | Research payment | Cash or cash equivalent | Drug | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2021 |
| 2021-03-01 | Mylan Technologies Inc. | $292 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-03-01 | Mylan Technologies Inc. | $92 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-03-01 | Mylan Technologies Inc. | $22 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-03-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-03-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-02-01 | Mylan Technologies Inc. | $303 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-02-01 | Mylan Technologies Inc. | $96 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-02-01 | Mylan Technologies Inc. | $23 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-02-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-02-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-01-20 | Genentech, Inc. | $24,696 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII | 2021 |
| 2021-01-13 | Genentech, Inc. | $17,424 | Research payment | Cash or cash equivalent | Drug | VA2 PHIII RHINE | 2021 |
| 2021-01-01 | Mylan Technologies Inc. | $301 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-01-01 | Mylan Technologies Inc. | $95 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-01-01 | Mylan Technologies Inc. | $23 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-01-01 | Mylan Technologies Inc. | $21 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2021-01-01 | Mylan Technologies Inc. | $8 | Research payment | In-kind items and services | MYL-1701P | A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Sa | 2021 |
| 2020-12-18 | Genentech, Inc. | $9,132 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-12-16 | Genentech, Inc. | $51,506 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-12-16 | Genentech, Inc. | $1,784 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-12-11 | Genentech, Inc. | $105,215 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-12-11 | Genentech, Inc. | $5,930 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-12-11 | Genentech, Inc. | $5,537 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2020 |
| 2020-12-11 | Genentech, Inc. | $2,995 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2020 |
| 2020-12-09 | Genentech, Inc. | $45,795 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-11-23 | Genentech, Inc. | $3,673 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2020 |
| 2020-11-23 | Genentech, Inc. | $615 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-11-20 | Genentech, Inc. | $9,148 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-11-20 | Genentech, Inc. | $516 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-11-20 | Genentech, Inc. | $279 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-11-03 | Genentech, Inc. | $43,040 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-10-27 | Genentech, Inc. | $31,400 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-10-14 | Genentech, Inc. | $22,819 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-09-28 | Genentech, Inc. | $1,896 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-09-23 | Genentech, Inc. | $9,970 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-09-22 | Genentech, Inc. | $56,094 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-09-16 | Genentech, Inc. | $60,449 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-09-01 | Genentech, Inc. | $12,804 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-08-27 | Genentech, Inc. | $85 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-08-25 | Genentech, Inc. | $1,627 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-08-10 | Genentech, Inc. | $1,808 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-07-29 | Genentech, Inc. | $34,388 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-07-13 | Genentech, Inc. | $20,493 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-07-01 | Genentech, Inc. | $7,133 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-07-01 | Genentech, Inc. | $4,133 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-07-01 | Genentech, Inc. | $834 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-07-01 | Genentech, Inc. | $22 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-06-17 | Genentech, Inc. | $45,189 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-06-17 | Genentech, Inc. | $8,480 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-06-08 | Genentech, Inc. | $19,875 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-06-08 | Genentech, Inc. | $14,100 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-06-01 | Genentech, Inc. | $12,018 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-06-01 | Genentech, Inc. | $730 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-05-01 | Genentech, Inc. | $4,051 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-05-01 | Genentech, Inc. | $1,630 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-05-01 | Genentech, Inc. | $668 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-04-27 | Genentech, Inc. | $4,773 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-04-22 | Genentech, Inc. | $37,996 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-04-20 | Genentech, Inc. | $96 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-04-14 | Genentech, Inc. | $43,328 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-04-14 | Genentech, Inc. | $1,837 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-04-06 | Genentech, Inc. | $20,766 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-04-02 | Genentech, Inc. | $9,707 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-04-02 | Genentech, Inc. | $9,039 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-03-17 | Genentech, Inc. | $54,765 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-03-12 | Genentech, Inc. | $21,675 | Research payment | Cash or cash equivalent | Lucentis Biological, Ophthalmology | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-03-05 | Genentech, Inc. | $496 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-03-05 | Genentech, Inc. | $248 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-03-03 | Genentech, Inc. | $5,295 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-03-03 | Genentech, Inc. | $1,035 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-03-02 | Genentech, Inc. | $23,237 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-02-13 | Genentech, Inc. | $127 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE 2 OF RO7171009 IN GA | 2020 |
| 2020-01-28 | Genentech, Inc. | $46,779 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2020 |
| 2020-01-28 | Genentech, Inc. | $3,569 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2020 |
| 2020-01-23 | Genentech, Inc. | $49,979 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-01-14 | Genentech, Inc. | $3,241 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-01-13 | Genentech, Inc. | $20,318 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2020 |
| 2020-01-13 | Genentech, Inc. | $3,000 | Research payment | Cash or cash equivalent | Lucentis Biological, Ophthalmology | STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA | 2020 |
| 2020-01-09 | Genentech, Inc. | $52,400 | Research payment | Cash or cash equivalent | Lucentis Biological, Ophthalmology | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2020 |
| 2020-01-03 | Genentech, Inc. | $1,432 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2020 |
| 2020-01-02 | Genentech, Inc. | $1,686 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2020 |
| 2019-12-18 | Genentech, Inc. | $20,792 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2019 |
| 2019-12-13 | Genentech, Inc. | $3,674 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2019 |
| 2019-12-13 | Genentech, Inc. | $3,568 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2019 |
| 2019-12-03 | Genentech, Inc. | $3,009 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2019 |
| 2019-11-13 | Genentech, Inc. | $2,003 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-11-04 | Genentech, Inc. | $5,438 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2019 |
| 2019-11-04 | Genentech, Inc. | $435 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2019 |
| 2019-10-29 | Genentech, Inc. | $15,644 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-29 | Genentech, Inc. | $299 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-29 | Genentech, Inc. | $293 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-24 | Genentech, Inc. | $26,339 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-10-24 | Genentech, Inc. | $18,274 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII RHINE | 2019 |
| 2019-10-22 | Genentech, Inc. | $4,301 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-22 | Genentech, Inc. | $600 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-22 | Genentech, Inc. | $307 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-17 | Genentech, Inc. | $3,363 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-08 | Genentech, Inc. | $81 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-10-02 | Genentech, Inc. | $5,130 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2019 |
| 2019-10-02 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | VA2 PHIII | 2019 |
| 2019-10-02 | Genentech, Inc. | $957 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2019 |
| 2019-09-24 | Genentech, Inc. | $2,855 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $2,574 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $234 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $221 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $172 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $162 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $159 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $146 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $146 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $146 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $146 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $140 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $127 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $127 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $122 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $95 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $81 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $81 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $81 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $65 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-24 | Genentech, Inc. | $30 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | LUCENTIS FSV4 LAD AMD LADDER | 2019 |
| 2019-09-23 | Genentech, Inc. | $24,770 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2019 |
| 2019-09-19 | Genentech, Inc. | $46,702 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM FOR RANIBIZUMAB | 2019 |
The latest 200 records of 252.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Nashville-Davidson, TN, county Davidson County, TN, state Tennessee; placed by its city name.
| Measure | Place (city or town) Nashville-Davidson, TN | County Davidson County, TN | State Tennessee |
|---|---|---|---|
| Population B01003 | 690,130 | 715,388 | 7,066,383 |
| Population, 2020 census P1 | 689,447 | 715,884 | 6,910,840 |
| Median age B01002 | 34.5 | 34.6 | 38.9 |
| Under 18 B01001 | 20.7% | 20.7% | 22.2% |
| 65 and over B01001 | 12.7% | 12.9% | 17.1% |
| Households B11001 | 313,513 | 324,907 | 2,824,277 |
| Foreign born B05002 | 15.3% | 15.0% | 6.1% |
| Median household income B19013 | $77,371 | $77,853 | $69,595 |
| Median family income B19113 | $98,376 | $99,460 | $87,314 |
| Per capita income B19301 | $49,061 | $50,640 | $39,437 |
| Poverty rate B17001 | 14.1% | 13.9% | 13.8% |
| Unemployment rate B23025 | 4.5% | 4.5% | 4.7% |
| Civilian labor force B23025 | 407,433 | 421,061 | 3,527,571 |
| Mean commute (minutes) B08013 | 24.7 | 24.7 | 25.7 |
| Bachelor's degree or higher B15003 | 48.0% | 48.4% | 31.1% |
| Housing units B25001 | 344,794 | 357,113 | 3,143,670 |
| Owner-occupied B25003 | 52.4% | 52.8% | 66.9% |
| Renters B25003 | 47.6% | 47.2% | 33.1% |
| Median home value B25077 | $413,600 | $417,400 | $286,700 |
| Median gross rent B25064 | $1,586 | $1,582 | $1,189 |
| White, not Hispanic B03002 | 52.6% | 53.2% | 71.0% |
| Black B03002 | 24.5% | 24.3% | 15.4% |
| Hispanic or Latino B03002 | 14.1% | 13.9% | 7.4% |
| Asian B03002 | 3.5% | 3.4% | 1.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Nashville-Davidson, TN.
Comments